Goltor

Goltor is an oral prescription medication that combines the statin simvastatin with the cholesterol absorption inhibitor ezetimibe. It is marketed in the European Union and is supplied as a tablet formulation, though specific strength information is not disclosed. The combination targets both endogenous cholesterol synthesis and intestinal cholesterol uptake, providing a dual approach to managing elevated lipid levels in patients with hypercholesterolemia or mixed dyslipidemia.

Goltor is indicated for the treatment of lipid disorders where a single‑agent approach has not achieved target cholesterol levels.

- Adjunct therapy for primary hypercholesterolemia when diet and lifestyle changes alone are insufficient. - Management of mixed dyslipidemia characterized by elevated LDL‑cholesterol and triglycerides. - Secondary prevention of cardiovascular events in patients with established atherosclerotic disease. - Use in adults who require additional LDL‑cholesterol reduction beyond that achieved with a statin alone.

The safety profile of Goltor reflects the combined effects of simvastatin and ezetimibe, with side effects ranging from mild to rare serious events.

Common: - Headache or dizziness, often transient and mild. - Muscle aches, cramps, or generalized weakness without loss of strength. - Abdominal discomfort, nausea, or diarrhea that usually resolves with continued therapy. - Elevated liver enzymes detected on routine laboratory testing. - Fatigue or general malaise reported by some patients. - Constipation or mild gastrointestinal upset.

Serious: - Severe muscle injury (rhabdomyolysis) presenting with muscle pain, dark urine, or acute kidney injury. - Significant liver injury manifested as jaundice, hepatitis, or marked transaminase elevation. - Allergic reactions including rash, angioedema, or anaphylactic shock.

When prescribing Goltor, clinicians should evaluate patient history and monitor laboratory parameters to minimize risk.

- Assess baseline liver function tests and repeat periodically during treatment. - Screen for a history of muscle disorders, especially when combined with other lipid‑lowering agents. - Use caution in patients with renal impairment or hypothyroidism, which can increase muscle toxicity. - Avoid use during pregnancy and lactation unless the potential benefit outweighs the risk. - Consider drug interactions with strong CYP3A4 inhibitors that may raise simvastatin concentrations. - Educate patients to report unexplained muscle pain, weakness, or dark urine promptly.

Goltor may interact with several medications; understanding these interactions helps maintain efficacy and safety.

Avoid: - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors) – may increase simvastatin levels and risk of rhabdomyolysis. - Cyclosporine – enhances both simvastatin and ezetimibe exposure, raising toxicity risk. - Grapefruit juice – can elevate simvastatin concentrations and should be avoided.

Use with caution: - Anticoagulants such as warfarin – may require closer INR monitoring. - Fibrates (gemfibrozil, fenofibrate) – combined use can increase muscle‑related adverse events. - Niacin – may augment risk of hepatotoxicity when used together.